Assenagon Asset Management S.A. Grows Position in Disc Medicine, Inc. $IRON

Assenagon Asset Management S.A. boosted its position in Disc Medicine, Inc. (NASDAQ:IRON) by 3,329.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 357,836 shares of the company’s stock after acquiring an additional 347,403 shares during the quarter. Assenagon Asset Management S.A. owned 0.95% of Disc Medicine worth $28,416,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd acquired a new position in Disc Medicine during the 3rd quarter worth approximately $38,000. Avanza Fonder AB lifted its position in shares of Disc Medicine by 54.0% during the 3rd quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock worth $110,000 after purchasing an additional 585 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Disc Medicine by 8.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock worth $133,000 after purchasing an additional 206 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of Disc Medicine by 15,137.5% during the third quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock worth $161,000 after purchasing an additional 2,422 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Disc Medicine by 383.0% during the second quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company’s stock worth $211,000 after purchasing an additional 3,152 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on IRON shares. UBS Group restated an “overweight” rating on shares of Disc Medicine in a research note on Thursday, January 15th. Cantor Fitzgerald lowered their price objective on Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a report on Wednesday, January 21st. Morgan Stanley set a $75.00 target price on Disc Medicine in a research report on Tuesday, February 17th. Finally, BMO Capital Markets decreased their target price on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a research note on Tuesday, February 17th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $104.80.

Disc Medicine Price Performance

Shares of IRON opened at $62.55 on Thursday. Disc Medicine, Inc. has a 1-year low of $30.82 and a 1-year high of $99.50. The stock has a market cap of $2.39 billion, a PE ratio of -10.44 and a beta of 0.87. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 21.94. The firm has a fifty day moving average price of $68.17 and a 200 day moving average price of $75.70.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.69) by $0.07. The firm had revenue of ($19.88) million for the quarter, compared to analysts’ expectations of $0.15 million. As a group, sell-side analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Insider Activity at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 13,264 shares of Disc Medicine stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $833,775.04. Following the transaction, the chief executive officer owned 226,064 shares of the company’s stock, valued at $14,210,383.04. The trade was a 5.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Rahul Khara sold 6,500 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $78.69, for a total value of $511,485.00. Following the completion of the sale, the insider owned 37,793 shares of the company’s stock, valued at approximately $2,973,931.17. This represents a 14.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 54,522 shares of company stock valued at $3,579,979 over the last 90 days. 3.64% of the stock is owned by insiders.

Disc Medicine Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.